Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$2990.00
-90.00 (-2.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$204.5B
P/E
71.2x
↑EV/EBITDA
7.9x
↓ROE
1.2%
↑Gross Margin
41.1%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.4%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
-0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $95.90B · net income $2.84B · FCF $-1.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $95.90B | $95.90B | $89.23B | $81.00B | $42.30B |
| Net Income | $2.84B | $2.84B | $13.31B | $25.69B | $-44.70B |
| EBITDA | $16.34B | $16.34B | $25.27B | $26.52B | $-38.84B |
| EPS | 42.00 | 42.00 | 198.00 | 334.00 | -813.00 |
| Gross Margin | 41.1% | 41.1% | 46.8% | 44.8% | 43.8% |
| Operating Margin | 1.8% | 1.8% | 15.6% | 7.5% | -23.9% |
| Net Margin | 3.0% | 3.0% | 14.9% | 31.7% | -105.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.06 | 0.01 | 0.07 |
| Current Ratio | 5.10 | 5.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.95B | $-1.95B | $-1.38B | $8.18B | $-24.70B |
| Returns | |||||
| ROE | 1.2% | 1.2% | 5.8% | 12.3% | -24.3% |
| Valuation | |||||
| P/E | 71.19 | 71.19 | 22.47 | 11.42 | — |
| EV/EBITDA | 7.91 | 7.91 | 8.82 | 8.57 | — |
| P/B | 0.86 | 0.86 | 1.30 | 1.40 | 1.46 |
| Growth & Yield | |||||
| Revenue Growth | 7.5% | 7.5% | 10.2% | 91.5% | — |
| EPS Growth | -78.8% | -78.8% | -40.7% | 141.1% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
84.9%
EPS terminal req.
$265.31
Spread vs growth
-163.6%
5Y implied EPS CAGR
50.2%
EPS terminal req.
$321.03
Spread vs growth
-129.0%
10Y implied EPS CAGR
28.5%
EPS terminal req.
$517.02
Spread vs growth
-107.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.1%
Start / end P/E
21.1x → 71.2x
EPS bridge
198.00 → 42.00
Residual
-187.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.